Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Cantargia AB ( (SE:CANTA) ) is now available.
Cantargia will publish its annual results for 2025 on 20 February 2026 and will host an English-language audiocast and teleconference later that day, where CEO Hilde Steineger and CFO Patrik Renblad will present the results and take questions from investors, analysts and media, with the presentation subsequently made available on demand via the company’s website. The results presentation offers stakeholders a key opportunity to gauge the progress of Cantargia’s IL1RAP-based antibody pipeline, including flagship oncology candidate nadunolimab, and to assess how the completed sale of CAN10 to Otsuka may influence the company’s financial profile and strategic focus going forward.
The most recent analyst rating on (SE:CANTA) stock is a Buy with a SEK7.00 price target. To see the full list of analyst forecasts on Cantargia AB stock, see the SE:CANTA Stock Forecast page.
More about Cantargia AB
Cantargia AB is a Swedish biotechnology company listed on Nasdaq Stockholm that develops antibody-based treatments for life‑threatening diseases, built around a platform targeting the protein IL1RAP, which is implicated in several cancers and inflammatory conditions. Its lead oncology asset, nadunolimab (CAN04), is in clinical development mainly in combination with chemotherapy for pancreatic cancer and non-small cell lung cancer, where early data suggest enhanced efficacy versus chemotherapy alone, while its second program, CAN10 for serious autoimmune and inflammatory diseases, was acquired by Otsuka Pharmaceutical in 2025.
Average Trading Volume: 3,913,418
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.38B
For detailed information about CANTA stock, go to TipRanks’ Stock Analysis page.